Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Jan;94(1):1-17.
doi: 10.1254/jphs.94.1.

Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on

Affiliations
Free article
Review

Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on

Selvanayagam Nirthanan et al. J Pharmacol Sci. 2004 Jan.
Free article

Abstract

The discovery, about forty years ago, of alpha-bungarotoxin, a three-finger alpha-neurotoxin from Bungarus multicinctus venom, enabled the isolation of the nicotinic acetylcholine receptor (nAChR), making it one of the most thoroughly characterized receptors today. Since then, the sites of interaction between alpha-neurotoxins and nAChRs have largely been delineated, revealing the remarkable plasticity of the three-finger toxin fold that has optimally evolved to utilize different combinations of functional groups to generate a panoply of target specificities to discern subtle differences between nAChR subtypes. New facets in toxinology have now broadened the scope for the use of alpha-neurotoxins in scientific discovery. For instance, the development of short, combinatorial library-derived, synthetic peptides that bind with sub-nanomolar affinity to alpha-bungarotoxin and prevent its interaction with muscle nAChRs has led to the in vivo neutralization of experimental alpha-bungarotoxin envenomation, while the successful introduction of pharmatopes bearing "alpha-bungarotoxin-sensitive sites" into toxin-insensitive nAChRs has permitted the use of various alpha-neurotoxin tags to localize and characterize new receptor subtypes. More ambitious strategies can now be envisaged for engineering rationally designed novel activities on three-finger toxin scaffolds to generate lead peptides of therapeutic value that target the nicotinic pharmacopoeia. This review details the progress made towards achieving this goal.

PubMed Disclaimer